1 of 1
Story summary
- The Most Favored Nation (MFN) pricing policy under U.S. President Donald Trump has created uncertainty that delays the launch of new medicines in Europe.
- Executives report a 35% drop in EU drug launches since the MFN policy was introduced.
- Insmed has postponed European launches, fearing lower U.S. prices if entering Europe.
- Experts warn that delays could let Chinese biotechs fill the gap, with long-term implications for patient access.
